{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:20:50Z","timestamp":1788283250686,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573943"],"award-info":[{"award-number":["82573943"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,9,20]]},"DOI":"10.1038\/s41416-026-03522-x","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:01:47Z","timestamp":1784901707000},"page":"845-855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025)"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2755-7258","authenticated-orcid":false,"given":"Dan","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-3876","authenticated-orcid":false,"given":"Jianhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiujie","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7237-0245","authenticated-orcid":false,"given":"Chen","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8121-9685","authenticated-orcid":false,"given":"Jinghua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6034-8872","authenticated-orcid":false,"given":"Ke","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanji","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7508-274X","authenticated-orcid":false,"given":"Guanghai","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuirong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4018-3393","authenticated-orcid":false,"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1233-1689","authenticated-orcid":false,"given":"Chunyi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8304-3115","authenticated-orcid":false,"given":"Liwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2289-1521","authenticated-orcid":false,"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"3522_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop TF, Javed AA, Oba A, Koerkamp BG, Seufferlein T, Wilmink JW, et al. Pancreatic cancer. Lancet. 2025;405:1182\u2013202.","journal-title":"Lancet"},{"key":"3522_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu ZI, O'Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:7\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3522_CR3","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74;229\u201363.","DOI":"10.3322\/caac.21834"},{"key":"3522_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495\u2013501.","journal-title":"Nature"},{"key":"3522_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47\u201352.","journal-title":"Nature"},{"key":"3522_CR6","doi-asserted-by":"crossref","unstructured":"Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500\u20133.","DOI":"10.1038\/nm.2344"},{"key":"3522_CR7","doi-asserted-by":"crossref","unstructured":"Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47:1168\u201378.","DOI":"10.1038\/ng.3398"},{"key":"3522_CR8","doi-asserted-by":"crossref","unstructured":"Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O'Kane GM, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020;52:231\u201340.","DOI":"10.1038\/s41588-019-0566-9"},{"key":"3522_CR9","doi-asserted-by":"crossref","unstructured":"Zhou X, Hu K, Bailey P, Springfeld C, Roth S, Kurilov R, et al. Clinical impact of molecular subtyping of pancreatic cancer. Front Cell Dev Biol. 2021;9:743908.","DOI":"10.3389\/fcell.2021.743908"},{"key":"3522_CR10","unstructured":"Hao C, Wang L, Qin S, Dai G, Fu D, Li Q, et al. CSCO Clinical Guidelines for the Diagnosis and Treatment of Pancreatic Cancer (Version 2024). Chinese Society of Clinical Oncology (CSCO). 2024. https:\/\/meeting.csco.org.cn\/pdf\/web\/viewer.html?file=\/Upload\/Periodical\/20240813112958.pdf."},{"key":"3522_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2105\/AJPH.74.9.979","volume":"74","author":"A Fink","year":"1984","unstructured":"Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health. 1984;74:979\u201383.","journal-title":"Am J Public Health"},{"key":"3522_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103897","volume":"77","author":"X Zhang","year":"2022","unstructured":"Zhang X, Mao T, Zhang B, Xu H, Cui J, Jiao F, et al. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. EBioMedicine. 2022;77:103897.","journal-title":"EBioMedicine"},{"key":"3522_CR13","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","volume":"319","author":"C Hu","year":"2018","unstructured":"Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319:2401\u20139.","journal-title":"JAMA"},{"key":"3522_CR14","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-019-1382-1","volume":"571","author":"P Jonsson","year":"2019","unstructured":"Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019;571:576\u20139.","journal-title":"Nature"},{"key":"3522_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"3522_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703\u201313.","journal-title":"Nat Med"},{"key":"3522_CR17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/bjc.2014.418","volume":"111","author":"T Golan","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111:1132\u20138.","journal-title":"Br J Cancer"},{"key":"3522_CR18","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","volume":"38","author":"EM O'Reilly","year":"2020","unstructured":"O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation. J Clin Oncol. 2020;38:1378\u201388.","journal-title":"J Clin Oncol"},{"key":"3522_CR19","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2022;40:3929\u201339.","journal-title":"J Clin Oncol"},{"key":"3522_CR20","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1002\/cncr.33812","volume":"127","author":"P Momtaz","year":"2021","unstructured":"Momtaz P, O'Connor CA, Chou JF, Capanu M, Park W, Bandlamudi C, et al. Pancreas cancer and BRCA: a critical subset of patients with improving therapeutic outcomes. Cancer. 2021;127:4393\u2013402.","journal-title":"Cancer"},{"key":"3522_CR21","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.21.00003","volume":"39","author":"KA Reiss","year":"2021","unstructured":"Reiss KA, Mick R, O'Hara MH, Teitelbaum U, Karasic TB, Schneider C, et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39:2497\u2013505.","journal-title":"J Clin Oncol"},{"key":"3522_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaoncol.2021.0006","volume":"7","author":"M Javle","year":"2021","unstructured":"Javle M, Shacham-Shmueli E, Xiao L, Varadhachary G, Halpern N, Fogelman D, et al. Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants: findings from 2 phase 2 nonrandomized clinical trials. JAMA Oncol. 2021;7:693\u20139.","journal-title":"JAMA Oncol"},{"key":"3522_CR23","doi-asserted-by":"crossref","unstructured":"Waters AM, Der CJ. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harbor Perspect Med. 2018;8:a031435.","DOI":"10.1101\/cshperspect.a031435"},{"key":"3522_CR24","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1093\/annonc\/mdx343","volume":"28","author":"B Schultheis","year":"2017","unstructured":"Schultheis B, Reuter D, Ebert MP, Siveke J, Kerkhoff A, Berdel WE, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Ann Oncol. 2017;28:2429\u201335.","journal-title":"Ann Oncol"},{"key":"3522_CR25","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1200\/JCO.22.02630","volume":"41","author":"S Qin","year":"2023","unstructured":"Qin S, Li J, Bai Y, Wang Z, Chen Z, Xu R, et al. Nimotuzumab plus gemcitabine for K-Ras wild-type locally advanced or metastatic pancreatic cancer. J Clin Oncol. 2023;41:5163\u201373.","journal-title":"J Clin Oncol"},{"key":"3522_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med. 2023;388:33\u201343.","journal-title":"N Engl J Med"},{"key":"3522_CR27","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, et al. Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation. J Clin Oncol. 2023;41:4097\u2013106.","journal-title":"J Clin Oncol"},{"key":"3522_CR28","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1200\/JCO.2025.43.4_suppl.724","volume":"43","author":"AI Spira","year":"2025","unstructured":"Spira AI, Papadopoulos KP, Kim DW, Parikh AR, Barve MA, Powderly JD, et al. Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. J Clin Oncol. 2025;43:724.","journal-title":"J Clin Oncol"},{"key":"3522_CR29","doi-asserted-by":"publisher","first-page":"S1273","DOI":"10.1016\/j.annonc.2023.10.025","volume":"34","author":"C Zhou","year":"2023","unstructured":"Zhou C, Li W, Song Z, Zhang Y, Zhang Y, Huang D, et al. LBA33 A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation. Ann Oncol. 2023;34:S1273.","journal-title":"Ann Oncol"},{"key":"3522_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1200\/JCO.2025.43.4_suppl.722","volume":"43","author":"I Garrido-Laguna","year":"2025","unstructured":"Garrido-Laguna I, Wolpin BM, Park W, Azad NS, Spira AI, Starodub A, et al. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2025;43:722.","journal-title":"J Clin Oncol"},{"key":"3522_CR31","doi-asserted-by":"publisher","first-page":"LB281","DOI":"10.1158\/1538-7445.AM2025-LB281","volume":"85","author":"S Kar","year":"2025","unstructured":"Kar S, Zhuang Y, Ahler E, Lai LP, Starodub A, Spira A, et al. Abstract LB281: Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies. Cancer Res. 2025;85:LB281.","journal-title":"Cancer Res"},{"key":"3522_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1158\/1541-7786.MCR-22-0626","volume":"21","author":"AT Ciner","year":"2023","unstructured":"Ciner AT, Jiang Y, Hausner P. BRAF-driven pancreatic cancer: prevalence, molecular features, and therapeutic opportunities. Mol Cancer Res. 2023;21:293\u2013300.","journal-title":"Mol Cancer Res"},{"key":"3522_CR33","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"JJ Grob","year":"2015","unstructured":"Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16:1389\u201398.","journal-title":"Lancet Oncol"},{"key":"3522_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goab031","volume":"10","author":"HS Li","year":"2022","unstructured":"Li HS, Yang K, Wang Y. Remarkable response of BRAF (V600E)-mutated metastatic pancreatic cancer to BRAF\/MEK inhibition: a case report. Gastroenterol Report. 2022;10:goab031.","journal-title":"Gastroenterol Report"},{"key":"3522_CR35","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1200\/JCO.20.00762","volume":"38","author":"AKS Salama","year":"2020","unstructured":"Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, et al. Dabrafenib and trametinib in patients with tumors with BRAF(V600E) mutations: results of the NCI-MATCH trial subprotocol H. J Clin Oncol. 2020;38:3895\u2013904.","journal-title":"J Clin Oncol"},{"key":"3522_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102789","volume":"129","author":"L Jones","year":"2024","unstructured":"Jones L, Cunningham D, Starling N. HER-2 directed therapies across gastrointestinal tract cancers - a new frontier. Cancer Treat Rev. 2024;129:102789.","journal-title":"Cancer Treat Rev"},{"key":"3522_CR37","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/bjc.2012.18","volume":"106","author":"J Harder","year":"2012","unstructured":"Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P, et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer. 2012;106:1033\u20138.","journal-title":"Br J Cancer"},{"key":"3522_CR38","doi-asserted-by":"publisher","first-page":"12071","DOI":"10.1002\/cam4.5893","volume":"12","author":"EGE de Vries","year":"2023","unstructured":"de Vries EGE, R\u00fcschoff J, Lolkema M, Tabernero J, Gianni L, Voest E, et al. Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma. Cancer Med. 2023;12:12071\u201383.","journal-title":"Cancer Med"},{"key":"3522_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonz\u00e1lez-Mart\u00edn A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42:47\u201358.","journal-title":"J Clin Oncol"},{"key":"3522_CR40","doi-asserted-by":"publisher","first-page":"TPS4667","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4667","volume":"38","author":"W Park","year":"2020","unstructured":"Park W, O'Reilly EM, Furuse J, Kunieda F, Jie F, Kindler HL. Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2\u2013positive metastatic pancreatic cancer (mPC). J Clin Oncol. 2020;38:TPS4667.","journal-title":"J Clin Oncol"},{"key":"3522_CR41","unstructured":"Astellas Pharma Inc. Astellas confirms phase 2 GLEAM trial did not meet primary endpoint of overall survival in patients with metastatic pancreatic cancer. Astellas Newsroom. 2025. https:\/\/newsroom.astellas.com\/2025-10-13-Astellas-Confirms-Phase-2-GLEAM-Trial-Did-Not-Meet-Primary-Endpoint-of-Overall-Survival-in-Patients-with-Metastatic-Pancreatic-Cancer."},{"key":"3522_CR42","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1200\/JCO.23.02314","volume":"42","author":"C Qi","year":"2024","unstructured":"Qi C, Zhang P, Liu C, Zhang J, Zhou J, Yuan J, et al. Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: a pooled analysis of two early-phase trials. J Clin Oncol. 2024;42:2565\u201377.","journal-title":"J Clin Oncol"},{"key":"3522_CR43","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1200\/JCO.2024.42.16_suppl.4011","volume":"42","author":"J Hao","year":"2024","unstructured":"Hao J, Zheng L, Ruihong D, Jieer Y, Xu Q, Wang L-W, et al. Safety and efficacy of IBI389, an anti-CLDN18.2\/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: preliminary results from a phase 1 study. J Clin Oncol. 2024;42:4011.","journal-title":"J Clin Oncol"},{"key":"3522_CR44","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1200\/JCO.2025.43.16_suppl.4017","volume":"43","author":"X Yu","year":"2025","unstructured":"Yu X, Ying J, Enxiao L, Zhou A, Sun Y, Yue J, et al. Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): results from a phase I dose expansion cohort evaluating IBI343. J Clin Oncol. 2025;43:4017.","journal-title":"J Clin Oncol"},{"key":"3522_CR45","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","volume":"28","author":"GD Demetri","year":"2022","unstructured":"Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res. 2022;28:1302\u201312.","journal-title":"Clin Cancer Res"},{"key":"3522_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000522206","volume":"89","author":"D Dum","year":"2022","unstructured":"Dum D, Taherpour N, Menz A, H\u00f6flmayer D, V\u00f6lkel C, Hinsch A, et al. Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors. Pathobiology. 2022;89:245\u201358.","journal-title":"Pathobiology"},{"key":"3522_CR47","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol. 2021;32:746\u201356.","journal-title":"Ann Oncol"},{"key":"3522_CR48","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Therapeutics. 2021;20:2329\u201340.","journal-title":"Mol Cancer Therapeutics"},{"key":"3522_CR49","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol. 2022;23:1261\u201373.","journal-title":"Lancet Oncol"},{"key":"3522_CR50","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","volume":"28","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial. Nat Med. 2022;28:1640\u20135.","journal-title":"Nat Med"},{"key":"3522_CR51","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2023.41.16_suppl.3007","volume":"41","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Wu Y-L, Zheng X, Li D, Huang D, Li X, et al. A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. J Clin Oncol. 2023;41:3007.","journal-title":"J Clin Oncol"},{"key":"3522_CR52","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa2405008","volume":"392","author":"AM Schram","year":"2025","unstructured":"Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, et al. Efficacy of zenocutuzumab in NRG1 fusion-positive cancer. N Engl J Med. 2025;392:566\u201376.","journal-title":"N Engl J Med"},{"key":"3522_CR53","doi-asserted-by":"publisher","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2023.0137","volume":"20","author":"S Du","year":"2023","unstructured":"Du S, Zhang Y, Xu J. Current progress in cancer treatment by targeting FGFR signaling. Cancer Biol Med. 2023;20:490\u20139.","journal-title":"Cancer Biol Med"},{"key":"3522_CR54","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","volume":"30","author":"J Rod\u00f3n","year":"2024","unstructured":"Rod\u00f3n J, Damian S, Furqan M, Garc\u00eda-Donas J, Imai H, Italiano A, et al. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nat Med. 2024;30:1645\u201354.","journal-title":"Nat Med"},{"key":"3522_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103625","volume":"9","author":"M Saleh","year":"2024","unstructured":"Saleh M, Barve M, Subbiah V, Papadopoulos KP, Morgensztern D, Mettu NB, et al. Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies. ESMO Open. 2024;9:103625.","journal-title":"ESMO Open"},{"key":"3522_CR56","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","volume":"24","author":"S Pant","year":"2023","unstructured":"Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023;24:925\u201335.","journal-title":"Lancet Oncol"},{"key":"3522_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1\u201310.","journal-title":"J Clin Oncol"},{"key":"3522_CR58","doi-asserted-by":"crossref","unstructured":"Cheng K, Li X, Lv W, Zhao G, Zhou R, Chang C, et al. Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib\/II trial. Signal Transd Targeted Ther. 2024;321;9.","DOI":"10.1038\/s41392-024-02031-8"},{"key":"3522_CR59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejca.2022.03.033","volume":"169","author":"E Karamitopoulou","year":"2022","unstructured":"Karamitopoulou E, Andreou A, Wenning AS, Gloor B, Perren A. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity. Eur J Cancer. 2022;169:64\u201373.","journal-title":"Eur J Cancer"},{"key":"3522_CR60","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365.","journal-title":"Lancet Oncol"},{"key":"3522_CR61","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/2159-8290.CD-21-0450","volume":"12","author":"CF Friedman","year":"2022","unstructured":"Friedman CF, Hainsworth JD, Kurzrock R, Spigel DR, Burris HA, Sweeney CJ, et al. Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study. Cancer Discov. 2022;12:654\u201369.","journal-title":"Cancer Discov"},{"key":"3522_CR62","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-0099","volume":"26","author":"ZA Wainberg","year":"2020","unstructured":"Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, Chiorean EG, et al. Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. Clin Cancer Res. 2020;26:4814\u201322.","journal-title":"Clin Cancer Res"},{"key":"3522_CR63","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41392-024-01857-6","volume":"9","author":"H Sha","year":"2024","unstructured":"Sha H, Tong F, Ni J, Sun Y, Zhu Y, Qi L, et al. First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel\/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial. Signal Transduct Target Ther. 2024;9:143.","journal-title":"Signal Transduct Target Ther"},{"key":"3522_CR64","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padr\u00f3n","year":"2022","unstructured":"Padr\u00f3n LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28:1167\u201377.","journal-title":"Nat Med"},{"key":"3522_CR65","unstructured":"Clinical and Laboratory Standards Institute. Collection, Transport, Preparation, and Storage of Specimens for Molecular Methods. Wayne, PA2020. MM13."},{"key":"3522_CR66","unstructured":"Clinical and Laboratory Standards Institute. Molecular Diagnostic Methods for Infectious Diseases. Wayne, PA2015. MM03."},{"key":"3522_CR67","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pan.2020.11.022","volume":"21","author":"TCY Pang","year":"2021","unstructured":"Pang TCY, Po JW, Becker TM, Goldstein D, Pirola RC, Wilson JS, et al. Circulating tumour cells in pancreatic cancer: a systematic review and meta-analysis of clinicopathological implications. Pancreatology. 2021;21:103\u201314.","journal-title":"Pancreatology"},{"key":"3522_CR68","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2159-8290.CD-25-0323","volume":"16","author":"X Wang","year":"2026","unstructured":"Wang X, Wang H, Zhang M, Li H, Liu Y, Huang H, et al. Development and prospective validation of a cell-free DNA-based model for the early detection of pancreatic cancer. Cancer Discov. 2026;16:66\u201380.","journal-title":"Cancer Discov"},{"key":"3522_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202414982","volume":"12","author":"C Zhao","year":"2025","unstructured":"Zhao C, Wang Z, Kim H, Kong H, Lee J, Yang JZ, et al. Identification of tumor-specific surface proteins enables quantification of extracellular vesicle subtypes for early detection of pancreatic ductal adenocarcinoma. Adv Sci. 2025;12:e2414982.","journal-title":"Adv Sci"},{"key":"3522_CR70","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/annonc\/mdt176","volume":"24","author":"FC Bidard","year":"2013","unstructured":"Bidard FC, Huguet F, Louvet C, Mineur L, Bouch\u00e9 O, Chibaudel B, et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol. 2013;24:2057\u201361.","journal-title":"Ann Oncol"},{"key":"3522_CR71","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1158\/1535-7163.MCT-17-1298","volume":"18","author":"T Wei","year":"2019","unstructured":"Wei T, Zhang Q, Li X, Su W, Li G, Ma T, et al. Monitoring tumor burden in response to FOLFIRINOX chemotherapy via profiling circulating cell-free DNA in pancreatic cancer. Mol Cancer Therapeutics. 2019;18:196\u2013203.","journal-title":"Mol Cancer Therapeutics"},{"key":"3522_CR72","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.1158\/1078-0432.CCR-20-0950","volume":"26","author":"JB Bachet","year":"2020","unstructured":"Bachet JB, Blons H, Hammel P, Hariry IE, Portales F, Mineur L, et al. Circulating tumor DNA is prognostic and potentially predictive of eryaspase efficacy in second-line in patients with advanced pancreatic adenocarcinoma. Clin Cancer Res. 2020;26:5208\u201316.","journal-title":"Clin Cancer Res"},{"key":"3522_CR73","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3389\/fonc.2020.01220","volume":"10","author":"J Jiang","year":"2020","unstructured":"Jiang J, Ye S, Xu Y, Chang L, Hu X, Ru G, et al. Circulating tumor DNA as a potential marker to detect minimal residual disease and predict recurrence in pancreatic cancer. Front Oncol. 2020;10:1220.","journal-title":"Front Oncol"},{"key":"3522_CR74","first-page":"433","volume":"89","author":"J Kysucan","year":"2010","unstructured":"Kysucan J, Lovecek M, Klos D, Tozzi I, Koranda P, Buri\u00e1nkov\u00e1 E, et al. Pr\u00ednos PET\/CT v predoperacn\u00edm stagingu karcinomu pankreatu [Benefit of PET\/CT in the preoperative staging in pancreatic carcinomas]. Preapect Surg. 2010;89:433\u201340.","journal-title":"Preapect Surg"},{"key":"3522_CR75","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1245\/s10434-008-9992-0","volume":"15","author":"JM Farma","year":"2008","unstructured":"Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT, et al. PET\/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol. 2008;15:2465\u201371.","journal-title":"Ann Surg Oncol"},{"key":"3522_CR76","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220749","volume":"306","author":"Y Mori","year":"2023","unstructured":"Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. 2023;306:e220749.","journal-title":"Radiology"},{"key":"3522_CR77","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2967\/jnumed.120.253062","volume":"62","author":"M R\u00f6hrich","year":"2021","unstructured":"R\u00f6hrich M, Naumann P, Giesel FL, Choyke PL, Staudinger F, Wefers A, et al. Impact of (68)Ga-FAPI PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2021;62:779\u201386.","journal-title":"J Nucl Med"},{"key":"3522_CR78","first-page":"768","volume":"47","author":"X Ma","year":"2023","unstructured":"Ma X, Jin J. Research progress on the application of 68Ga-FAPI PET\/CT in digestive system malignant tumors. Int J Radiat Med Nucl Med. 2023;47:768\u201373.","journal-title":"Int J Radiat Med Nucl Med"},{"key":"3522_CR79","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1007\/s00259-022-05729-5","volume":"49","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Jia G, Pan G, Cao K, Yang Q, Meng H, et al. Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET\/MR and (18)F-FDG PET\/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49:2877\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3522_CR80","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1007\/s00259-021-05576-w","volume":"49","author":"Y Pang","year":"2022","unstructured":"Pang Y, Zhao L, Shang Q, Meng T, Zhao L, Feng L, et al. Positron emission tomography and computed tomography with [(68)Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49:1322\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3522_CR81","first-page":"1683","volume":"63","author":"KS Roth","year":"2022","unstructured":"Roth KS, Voltin CA, van Heek L, Wegen S, Schom\u00e4cker K, Fischer T, et al. Dual-tracer PET\/CT protocol with [(18)F]-FDG and [(68)Ga]Ga-FAPI-46 for cancer imaging: a proof of concept. J Nucl Med. 2022;63:1683\u20136.","journal-title":"J Nucl Med"},{"key":"3522_CR82","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","volume":"120","author":"W Wei","year":"2020","unstructured":"Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: concept, design, and applications. Chem Rev. 2020;120:3787\u2013851.","journal-title":"Chem Rev"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03522-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03522-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03522-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:03:06Z","timestamp":1788282186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03522-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9,20]]}},"alternative-id":["3522"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03522-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}